Astrazeneca plc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $58.7B+8.6% YoYTTM through 31 Dec 2025
Net Income $10.2B+45.3% YoYTTM through 31 Dec 2025
Free Cash Flow $11.8BTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Operating Margin | 23.4% |
| Net Margin | 17.4% |
Returns
21.0%ROE
9.0%ROA
15.1%ROIC
Balance Sheet Health
Debt / Equity0.51x
Current Ratio0.94x
Net Debt$19B
Cash & Equivalents$5.7B
Quality Metrics
Piotroski F-Score7 / 9
FCF Margin20.0%
Rule of 4027.7
Multi-Year Trend
RevenueFY2025: $58.7B
Diluted EPSFY2025: $6.54
Dividend
$2.15Per share, FY20261.28%Yield-5.1%5-yr growth
Capital Allocation
Capex Intensity4.8%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Oncology | $25.6B | +15.0% | View detailsTargeting mid-teens growth into 2026 and over $10 billion in combined risk-adjusted peak-year revenue. |
| Cardiovascular, Renal & Metabolism (CVRM) | $12.8B | +3.0% | |
| Respiratory & Immunology (R&I) | $8.9B | +13.0% | |
| Rare Disease | $9.1B | +4.0% | View detailsLaunches in over 75 countries and upcoming drivers like ICAN in IgAN position it for low double-digit CAGR. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.